

## **Hong Kong Pharmaceutical Holdings Limited**

(Incorporated in Bermuda with limited liability)

# 香港葯業集團有限公司\*

(於百慕達註冊成立之有限公司)

### 二零零一/二零零二年中期業績報告

#### Interim Report 2001/2002

香港葯業集團有限公司(「本公司」)董事會(「董事會」)欣然公佈本公司及其附屬公司(「本集團」)截至二零零一年九月三十日止六個月(「期間」)之未經審核簡明綜合中期業績連同比較數字。此等未經審核之中期財務報表已由本公司之審核委員會及核數師按香港會計師公會所頒佈之核數準則第700號進行審閱。

The Board of Directors (the "Directors") of Hong Kong Pharmaceutical Holdings Limited (the "Company") is pleased to announce the unaudited condensed consolidated interim results of the Company and its subsidiaries (the "Group") for the six months ended 30 September 2001 (the "Period") together with comparative figures. These interim financial statements have not been audited but have been reviewed by the Company's audit committee and the auditors in accordance with the Statement of Auditing Standard 700 issued by the Hong Kong Society of Accountants.

#### 簡明綜合損益表

# CONDENSED CONSOLIDATED PROFIT AND LOSS ACCOUNT

截至九月三十日止六個月 For the six months ended 30 September 二零零一年 二零零零年 2001 2000

(未經審核) (未經審核及重列) (Unaudited

			(Unaudited)	and restated)
		附註	千港元	千港元
		Notes	HK\$'000	HK\$'000
營業額	TURNOVER	2	27,379	13,765
銷售成本	Cost of sales		(15,636)	(7,395)
毛利	Gross profit		11,743	6,370
其他收入	Other revenue	3	2,048	2,335
分銷成本	Distribution costs		(14,301)	(6,356)
行政開支	Administrative expenses		(11,945)	(5,221)
其他經營	Other operating			
收入/(支出)	income/(expenses)		(5,463)	1,329
經營業務虧損	LOSS FROM OPERATING ACTIVITIES	4	(17,918)	(1,543)
融資成本	Finance costs	5	(3,064)	(2,990)
除税前虧損	LOSS BEFORE TAX		(20,982)	(4,533)
税項	Tax	6		
未計少數股東	LOSS BEFORE MINORITY			
權益前虧損	INTERESTS		(20,982)	(4,533)
少數股東權益	Minority interests		2,917	-
	•	IFC		
股東應佔日常 業務虧損淨額	NET LOSS FROM ORDINARY ACTIVITI ATTRIBUTABLE TO SHAREHOLDERS	_	(18,065)	(4,533)
每股虧損	LOSS PER SHARE	8		
基本	Basic		(1.32仙 cents)	(0.46仙 cents)
攤薄	Diluted		 不適用 N/A	 不適用 N/A

<sup>\*</sup> 只供識別 \* For identification only

1